Compare BBWI & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBWI | CRNX |
|---|---|---|
| Founded | 1963 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.9B |
| IPO Year | 1994 | 2018 |
| Metric | BBWI | CRNX |
|---|---|---|
| Price | $20.04 | $83.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 8 |
| Target Price | $24.88 | ★ $76.75 |
| AVG Volume (30 Days) | 4.9M | ★ 7.0M |
| Earning Date | 05-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $7,291,000,000.00 | $1,039,000.00 |
| Revenue This Year | N/A | $720.10 |
| Revenue Next Year | $2.19 | $184.67 |
| P/E Ratio | $22.07 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.28 | $25.83 |
| 52 Week High | $32.32 | $84.00 |
| Indicator | BBWI | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 49.02 | 91.05 |
| Support Level | $18.81 | $43.40 |
| Resistance Level | $21.46 | N/A |
| Average True Range (ATR) | 0.80 | 0.19 |
| MACD | -0.09 | -1.44 |
| Stochastic Oscillator | 39.51 | 40.51 |
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with just 4% of sales from international markets in fiscal 2025. For fiscal 2025, 77% of sales stemmed from the brick-and-mortar network of more than 1,900 retail stores, similar to 2024 levels, as consumer shopping patterns remained normal. Future growth is expected from store upgrades, digital and international channels, as well as adjacent category expansions like men's and lip.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.